SCHEMBL6921762

SCHEMBL6921762

COc1ccc([N+](=O)[O-])cc1OCC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 1/20 0.63
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ POLB P06746 2/20 0.55
▸ KMT2A Q03164 4/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ HTT P42858 3/20 0.54
▸ MAPT P10636 4/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ GAA P10253 1/20 0.53
▸ CRHBP P24387 1/20 0.53
▸ CRHR2 Q13324 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ PKM P14618 1/20 0.52
▸ LMNA P02545 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1531280 0.94 PTGDR2 (0.63) PTGDR2SMN1; SMN2POLBKMT2AMEN1
SCHEMBL3480872 0.91 PTGDR2 (0.69) PTGDR2SMN1; SMN2POLBKMT2AMEN1
SCHEMBL1106918 0.87 KMT2A (0.56) SMN1; SMN2POLBKMT2AMEN1HTT
SCHEMBL6928011 0.87 KMT2A (0.53) PTGDR2SMN1; SMN2POLBKMT2AMEN1
SCHEMBL20042055 0.83 ALDH1A1 (0.55) SMN1; SMN2POLBKMT2AMEN1HTT
SCHEMBL22502222 0.83 KMT2A (0.50) PTGDR2SMN1; SMN2POLBKMT2AMEN1
SCHEMBL15362097 0.82 PTGDR2 (0.63) PTGDR2SMN1; SMN2POLBKMT2AMEN1
SCHEMBL1531330 0.82 KMT2A (0.54) SMN1; SMN2POLBKMT2AMEN1HTT
SCHEMBL6573363 0.82 PTGDR2 (0.66) PTGDR2SMN1; SMN2POLBKMT2AMEN1
SCHEMBL31324800 0.82 PTGDR2 (0.62) PTGDR2SMN1; SMN2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001766-B1 COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2003-04-09 — — EP disclosed
US-6515027-B1 Ligands, agonists or antagonists, of the CC chemokine receptor CC-CKR5 SMITHKLINE BEECHAM CORP. 2003-02-04 — — US disclosed
EP-1001766-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2001-04-04 — — EP disclosed
EP-1001766-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 — — EP disclosed
WO-1999001127-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 — — WO disclosed
Send feedback